VIDEO: Ocular Therapeutix shifts to retina-focused treatments

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.

Two phase 3 macular degeneration programs investigating Axpaxli, a sustained-release polymer that delivers a tyrosine kinase inhibitor, are underway at Ocular Therapeutix.

“Early studies in macular degeneration as well as diabetic retinopathy have been very promising,” Kaiser said.

Published by:

Sources/Disclosures

Collapse

Source:

Kaiser P. AAO 2024 retina showcase. Presented at: Eyecelerator@AAO; Oct. 17, 2024; Chicago.

Disclosures:
Kaiser reports being the chief development officer at Ocular Therapeutix.

Read more about

This post was originally published on this site